|
1
|
Tikhmyanova N and Golemis EA: NEDD9 and
BCAR1 negatively regulate E-cadherin membrane localization, and
promote E-cadherin degradation. PLoS One. 6:e221022011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Defilippi P, Di Stefano P and Cabodi S:
p130Cas: A versatile scaffold in signaling networks. Trends Cell
Biol. 16:257–263. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh M, Cowell L, Seo S, O'Neill G and
Golemis E: Molecular basis for HEF1/NEDD9/Cas-L action as a
multifunctional co-ordinator of invasion, apoptosis and cell cycle.
Cell Biochem Biophys. 48:54–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tikhmyanova N, Little JL and Golemis EA:
CAS proteins in normal and pathological cell growth control. Cell
Mol Life Sci. 67:1025–1048. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Neill GM, Seo S, Serebriiskii IG, Lessin
SR and Golemis EA: A new central scaffold for metastasis: Parsing
HEF1/Cas-L/NEDD9. Cancer Res. 67:8975–8979. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Izumchenko E, Singh MK, Plotnikova OV,
Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M,
Egleston BL, Klein-Szanto A, et al: NEDD9 promotes oncogenic
signaling in mammary tumor development. Cancer Res. 69:7198–7206.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shagisultanova E, Gaponova AV, Gabbasov R,
Nicolas E and Golemis EA: Preclinical and clinical studies of the
NEDD9 scaffold protein in cancer and other diseases. Gene.
567:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balch CM, Gershenwald JE, Soong S,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Flier S, Brinkman A, Look MP, Kok
EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC and Foekens JA:
Bcar1/p130Cas protein and primary breast cancer: Prognosis and
response to tamoxifen treatment. J Natl Cancer Inst. 92:120–127.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Natarajan M, Stewart JE, Golemis EA,
Pugacheva EN, Alexandropoulos K, Cox BD, Wang W, Grammer JR and
Gladson CL: HEF1 is a necessary and specific downstream effector of
FAK that promotes the migration of glioblastoma cells. Oncogene.
25:1721–1732. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim M, Gans JD, Nogueira C, Wang A, Paik
JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bui LC, Tomkiewicz C, Chevallier A, Pierre
S, Bats AS, Mota S, Raingeaud J, Pierre J, Diry M, Transy C, et al:
Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants
on cell migration and plasticity. Oncogene. 28:3642–3651. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rozenberg GI, Monahan KB, Torrice C, Bear
JE and Sharpless NE: Metastasis in an orthotopic murine model of
melanoma is independent of RAS/RAF mutation. Melanoma Res.
20:361–371. 2010.PubMed/NCBI
|
|
16
|
Singh MK, Izumchenko E, Klein-Szanto AJ,
Egleston BL, Wolfson M and Golemis EA: Enhanced genetic instability
and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Cancer Res. 70:8907–8916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu
W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dadke D, Jarnik M, Pugacheva EN, Singh MK
and Golemis EA: Deregulation of HEF1 impairs M-phase progression by
disrupting the RhoA activation cycle. Mol Biol Cell. 17:1204–1217.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Domingues MJ, Rambow F, Job B, Papon L,
Liu W, Larue L and Bonaventure J: β-catenin inhibitor ICAT
modulates the invasive motility of melanoma cells. Cancer Res.
74:1983–1995. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee TK, Murthy SR, Cawley NX, Dhanvantari
S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, Wesley RA, et al: An
N-terminal truncated carboxypeptidase E splice isoform induces
tumor growth and is a biomarker for predicting future metastasis in
human cancers. J Clin Invest. 121:880–892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo S, Iwata S, Yamada T, Inoue Y,
Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H,
Hosono O, et al: Impact of the integrin signaling adaptor protein
NEDD9 on prognosis and metastatic behavior of human lung cancer.
Clin Cancer Res. 18:6326–6338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo
C, Wang X, Liu H, Deng L, Li C, et al: NEDD9 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Int J Cancer.
134:2294–2304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang SS, Wu LH, Liu Q, Chen KS and Zhang
XF: Elevated expression of NEDD9 is associated with metastatic
activity in gastric cancer. Onco Targets Ther. 8:633–640. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB,
Wei YZ, Wu ZJ, Cheng GJ, Wang F, Ni F, et al: NEDD9 overexpression
correlates with poor prognosis in gastric cancer. Tumour Biol.
35:6351–6356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi R, Wang L, Wang T, Xu J, Wang F and Xu
M: NEDD9 overexpression correlates with the progression and
prognosis in gastric carcinoma. Med Oncol. 31:8522014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karabulut M, Alis H, Afsar CU, Karabulut
S, Kocatas A, Oguz H and Aykan NF: Serum neural precursor
cell-expressed, developmentally down regulated 9 (NEDD9) level may
have a prognostic role in patients with gastric cancer. Biomed
Pharmacother. 73:140–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY,
Wu YM, Lu YF, Yu LH, Li JP and Li ZS: Expression of NEDD9 in
pancreatic ductal adenocarcinoma and its clinical significance.
Tumour Biol. 34:895–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu P, Wang ZP, Dang Z, Zheng ZG, Li X,
Zhou L, Ding R, Yue SQ and Dou KF: Expression of NEDD9 in
hepatocellular carcinoma and its clinical significance. Oncol Rep.
33:2375–2383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li P, Zhou H, Zhu X, Ma G, Liu C, Lin B
and Mao W: High expression of NEDD9 predicts adverse outcomes of
colorectal cancer patients. Int J Clin Exp Pathol. 7:2565–2570.
2014.PubMed/NCBI
|
